Bhava (Bevacizumab) is used in the treatment of metastatic Colorectal Cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer patients.
As per a WHO report of 2020, out of the total cancer cases reported in Mexico, breast, prostate, colorectal and thyroid were amongst the common cancer cases registered.
Zydus had developed and launched the Bevacizumab biosimilar developed in-house by the research team at the Zydus Research Centre (ZRC) in 2015 in India under the brand name Bryxta. Since then, an estimated 50,000 patients have been treated with the therapy.
With twelve lifesaving biosimilars already launched in the market, Zydus has been bridging the unmet need ...
More News
|
|